Ariad Study Continues Ramping Shares (ARIA)

Posted in pre-market 
September 14th, 2009

Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is one of the top gainers this morning after announcing the result of first interim analysis of Phase 3 ‘Succeed Trial’ of Oral Ridaforolimus in metastatic sarcoma… the independent Data Monitoring Committee of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis and has recommended that it continues to full patient enrollment and completion.  The safety data. At 8:50 AM EST shares are up close to 16% at $3.03 on over 800,000 shares.  Average volume is 2.9 million shares.  -JON OGG

Comments are closed